Baxter International, Inc. Marks World Hemophilia Day by Reinforcing Commitment to Addressing Disparities in Care and Sharing New Vision for the Future

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced its continued commitment to the hemophilia community to close the gap in hemophilia care and the company’s vision to pursue a bleed-free world for people living with this debilitating disorder on World Hemophilia Day. Approximately 400,000 people worldwide are living with hemophilia,1 with an estimated 75 percent remaining undiagnosed and receiving inadequate care or no care at all.2 To address these disparities in care, Baxter continues its role as the founding sponsor of the World Federation of Hemophilia’s (WFH) Global Alliance for Progress (GAP) program. This healthcare development project, now in its 11th year, aims to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in developing countries. Since the program’s initiation in 2003, more than 93,000 people in 20 countries have been diagnosed with bleeding disorders (approximately 56,000 with hemophilia).3 Baxter has donated more than 16 million international units of product over the past three years through its humanitarian aid partners, the WFH and AmeriCares to provide factor replacement treatment in developing countries where it may not otherwise be available.